SSRIs for hot flashes

a systematic review and meta-analysis of randomized trials.

Taghreed Shams, Belal Firwana, Farida Habib, Abeer Alshahrani, Badria Alnouh, Mohammad Hassan Murad, Mazen Ferwana

Research output: Contribution to journalReview articleResearchpeer-review

44 Citations (Scopus)

Abstract

Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 % CI -1.46 to -0.37; I(2) = 21 %) and severity assessed by various scales (standardized difference in means -0.34; 95 % CI -0.59 to -0.10; I(2) = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

Original languageEnglish
Pages (from-to)204-213
Number of pages10
JournalJournal of General Internal Medicine
Volume29
Issue number1
DOIs
Publication statusPublished - 1 Jan 2014

Fingerprint

Hot Flashes
Meta-Analysis
Randomized Controlled Trials
Placebos
Postmenopause
Citalopram
Menopause
MEDLINE
Outcome Assessment (Health Care)
Therapeutics

Cite this

Shams, Taghreed ; Firwana, Belal ; Habib, Farida ; Alshahrani, Abeer ; Alnouh, Badria ; Murad, Mohammad Hassan ; Ferwana, Mazen. / SSRIs for hot flashes : a systematic review and meta-analysis of randomized trials. In: Journal of General Internal Medicine. 2014 ; Vol. 29, No. 1. pp. 204-213.
@article{21e6d214e40b47df9c0ca001299c085e,
title = "SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.",
abstract = "Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 {\%} CI -1.46 to -0.37; I(2) = 21 {\%}) and severity assessed by various scales (standardized difference in means -0.34; 95 {\%} CI -0.59 to -0.10; I(2) = 47 {\%}). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.",
author = "Taghreed Shams and Belal Firwana and Farida Habib and Abeer Alshahrani and Badria Alnouh and Murad, {Mohammad Hassan} and Mazen Ferwana",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s11606-013-2535-9",
language = "English",
volume = "29",
pages = "204--213",
journal = "Journal of General Internal Medicine",
issn = "0884-8734",
publisher = "Springer Nature",
number = "1",

}

SSRIs for hot flashes : a systematic review and meta-analysis of randomized trials. / Shams, Taghreed; Firwana, Belal; Habib, Farida; Alshahrani, Abeer; Alnouh, Badria; Murad, Mohammad Hassan; Ferwana, Mazen.

In: Journal of General Internal Medicine, Vol. 29, No. 1, 01.01.2014, p. 204-213.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - SSRIs for hot flashes

T2 - a systematic review and meta-analysis of randomized trials.

AU - Shams, Taghreed

AU - Firwana, Belal

AU - Habib, Farida

AU - Alshahrani, Abeer

AU - Alnouh, Badria

AU - Murad, Mohammad Hassan

AU - Ferwana, Mazen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 % CI -1.46 to -0.37; I(2) = 21 %) and severity assessed by various scales (standardized difference in means -0.34; 95 % CI -0.59 to -0.10; I(2) = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

AB - Hot flashes are the most commonly reported vasomotor symptom during the peri- and early post-menopausal period. To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means -0.93; 95 % CI -1.46 to -0.37; I(2) = 21 %) and severity assessed by various scales (standardized difference in means -0.34; 95 % CI -0.59 to -0.10; I(2) = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=84903462978&partnerID=8YFLogxK

U2 - 10.1007/s11606-013-2535-9

DO - 10.1007/s11606-013-2535-9

M3 - Review article

VL - 29

SP - 204

EP - 213

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

SN - 0884-8734

IS - 1

ER -